Skip to main content
. Author manuscript; available in PMC: 2020 Jul 27.
Published in final edited form as: Neuropharmacology. 2018 Nov 3;144:301–311. doi: 10.1016/j.neuropharm.2018.10.036

Table 1.

Oxytocin receptor activity of TC-OT-39 and carbetocin.

FLIPRTETRA®
Ca2+ Release		 DiscoveRx
β-Arrestin		 DiscoveRx Express
β-Arrestin
EC50 (nM)a
Oxytocin 0.30 ± 0.09 23 ± 22 44.7
TC-OT-39 5 ± 1 310 ± 260 480
Carbetocin 3 ± 1 5 ± 2 5.3
Vasopressin 5 ± 2 1600 ± 900 2680
Efficacy (% OXT Response)b
TC-OT-39 102 51 ± 6 48
Carbetocin 92 32 ± 5 32
Vasopressin 105 41 ± 6 38
a

Potencies and efficacies of the DiscoveRx Express cell lines were run as single points only.

b

Efficacies were calculated considering the oxytocin response as 100%. The DiscoveRx Express refers to the PathHunter™ eXpress β-Arrestin GPCR Kits using the assay-ready, frozen PathHunter™ eXpress cells available through the manufacturer.